262 Studies Now Enrolling
Interventional, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to assess the efficacy, safety and tolerability of Lu AF82422 in patients with Multiple System Atrophy
A Clinical Trial to Test the Medication Lu AF82422 for Safety and Efficacy in Treating Multiple System Atrophy (MSA)
| Sponsor: | Lundbeck |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAT9815 |
| U.S. Govt. ID: | NCT05104476 |
| Contact: | Michael Minyetty: 646-450-9859 / mm6068@cumc.columbia.edu |
Additional Study Information:
The purpose of this research study is to find out whether the experimental drug Lu AF82422 is safe and effective in people living with MSA. An experimental drug means the Food and Drug Administration (FDA) has not approved it for use by the general public
This study is closed
Do You Qualify?
| Diagnosis of possible or probable MSA | Yes | No |
| Less than 5 years since onset of symptoms | Yes | No |
| Diagnosis of any movement disorder that could mimic MSA eg: Parkinson's disease | Yes | No |
| Any past or current treatment with an active vaccine targeting alpha-synuclein | Yes | No |
| Two or more blood relatives with a history of MSA | Yes | No |